濟南高新(600807.SH)：擬收購艾克韋生物部分股權
格隆匯12月2日丨濟南高新(600807.SH)公佈，為加快推進業務戰略轉型，實現公司在生物醫療產業領域的佈局，培育新的利潤增長點，不斷增強公司盈利能力、持續發展能力，驅動公司未來高質量發展，公司全資子公司濟南高新實業發展有限公司(“濟高實業”)擬出資 22865萬元， 濟南高新財金投資有限公司(“濟高財金”)擬出資13920萬元，濟南高新盛和發展有限公司(“濟高盛和”)擬出資13615萬元，收購西隴科學股份有限公司(“西隴科學”)持有的山東艾克韋生物技術有限公司(“艾克韋生物”或“標的公司”)60%股權，此次收購完成後，濟高實業將持有艾克韋生物27.2202%股權，同時，西隴科學將其持有的剩餘13.7801%股權表決權委託濟高實業代為行使。
西隴科學承諾，艾克韋生物2022-2024年經審計的税後淨利潤分別不低於4900萬元、6300萬元、7800萬元，即業績承諾期間累計實現經審計後的税後淨利潤不低於1.9億元。
艾克韋生物為致力於臨牀醫學、分子診斷以及基因檢測技術產品和高通量檢測平台的開發、產業化和技術服務的創新型高新技術企業；分子診斷作為體外診斷高科技細分領域，是目前國內發展速度較快的生物醫療細分領域之一，艾克韋生物深耕分子診斷領域多年，未來具有較大的空間和良好的發展前景。
公司通過收購艾克韋生物，將為公司帶來生物醫療新主業，實現公司業務結構的變革和優化。艾克韋生物在分子檢測領域具有較強的研發和技術優勢、穩定的客户資源和良好的發展前景，將為公司帶來新的利潤增長點，有助於增強公司業績和持續盈利能力。
公司併購艾克韋生物後，將進一步在生物醫療產業領域深耕發展，不斷做大做強生物醫療業務，提升生物醫療業務規模和盈利水平，使生物醫療業務成為驅動公司未來高質量發展的核心引擎之一。同時公司生物醫療業務板塊的發展，也有助於促進公司產業園區業務產業資源的整合和集聚，實現與產業園區開發運營業務的有效協同和雙向賦能，集聚一批體外診斷、創新醫療器械等相關企業，促進公司產業園區運營管理水平的提升，最終實現公司整體的業務規模和盈利能力提升。此次交易完成後，艾克韋生物將納入公司合併報表範圍，預計會對公司未來業績產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
